ROCSS: Reinforcement of Closure of Stoma Site. A randomised controlled trial of reinforcement of closure of stoma site using a biological mesh.
ROCSS is a randomised controlled trial assessing the placement of biological mesh in order to reduce the rate of hernias at the site of stoma closure. Strattice is a well-established biological mesh/ tissue matrix which would be compared against a control arm of no mesh placement.
The Rationale for a Trial
Closure of complex and contaminated abdominal wounds is challenging and carries risks, including wound dehiscence and incisional hernias. Use of biological meshes in these situations may provide a safe method of reducing these complications, especially long-term incisional hernias. ROCSS will use stoma site closure as a model for biological mesh placement during any difficult contaminated abdominal wall closures.
Hernia at the site of stoma closure occurs in up to 30% of patients and is associated with adverse effects on quality of life. In up to 10% of cases, patients are submitted to complex re-operation which carries significant morbidity. Not all patients will report symptoms or undergo repair, as they do not wish to have a further major operation. Incisional hernias at the site of stomas closure form an important and well defined subgroup. If there is a measurable benefit from mesh insertion, elective use of a collagen mesh would warrant consideration in the closure of other difficult, contaminated abdominal wounds. This study will also provide useful information on the value of using a CT scan as an early diagnostic tool of herniation, which could then be used in future abdominal wall studies as a surrogate endpoint for clinical hernia.
The aim of the ROCSS trial is to assess whether a biological mesh (collagen tissue matrix) reduces the incidence of clinically detectable stoma closure site hernias at two years compared to standard closure techniques.
ROCSS is a prospective, multi-centre randomised controlled trial.
ROCSS is designed in two stages:
i) a feasibility study
ii) a Phase III multi-centre RCT
The feasibility phase will assess recruitment, the randomisation process and deliverability of the treatment.
The Phase III study will be a prospective, multi-centre RCT to determine if the use of a collagen tissue matrix (Strattice®) reduces the incidence of clinically detectable stoma closure site hernias at two years as compared to standard closure techniques.
The trial aims to randomise 560 patients in 2 years.
Objectives of the feasibility trial
To develop strategies for effective recruitment and randomisation
To assess the deliverability of the mesh placement technique.
Objectives of the main trial
To assess whether a collagen tissue matrix (Strattice) reduces the incidence of clinically detected stoma closure site hernias at two years compared to standard closure techniques.
Frequency of wound infections and seroma associated with the mesh.
Patient quality of life and pain experienced.
Cost effectiveness of the mesh insertion in stoma site closure and management of subsequent hernias.
Exploratory analysis to investigate the CT scan as an early surrogate marker of late clinical herniation:
Radiological hernia rate at one year post closure will be compared with the clinical hernia rate at 2 years to assess the value of using a CT scan as an early diagnostic tool of herniation
ROCSS Trial Surgical Technique
Occurence of clinically detected hernias at two years post closure
Radiological hernia rate at one year post closure. An exploratory analysis will compare radiological hernia rate at 1 year with clinical hernia rate at 2 years to assess the value of using a CT scan as an early diagnostic tool of incisional hernias
Surgical re-intervention rate
Surgical complications at 30 days and 1 year
Quality of life and post-operative pain
To randomise a patient please call 0800 953 0274
We will soon have an online application and we will let you know as soon as we go live.
ROCSS Study Office
Laura Magill (Trial Manager) Tel: 0121 415 9105 Email: email@example.com
Alex Vince (Trial Coordinator) Tel: 0121 415 9103 Email: firstname.lastname@example.org
Helen Lilly (Trial Administrator) Tel: 0121 415 9106 Email: email@example.com